Matthew Vincent Dolan - May 15, 2024 Form 4 Insider Report for DEXCOM INC (DXCM)

Role: EVP Strategy and Corporate Dev
Signature: By: /s/ Jereme M Sylvain For: Matthew Vincent Dolan
Stock symbol: DXCM
Transactions as of: May 15, 2024
Transactions value $: -$306,703
Form type: 4
Date filed: 5/16/2024, 04:04 PM
Previous filing: Apr 16, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DXCM	Common Stock	Sale	-$307K	-2.42K	-5.7%	$126.58	40.1K	May 15, 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	On December 15, 2023, Mr. Dolan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F2	Included in this number are 40,075 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 3,852 of which were granted on March 8, 2022 and shall vest through March 8, 2025 and 121 additional shares purchased pursuant to the DexCom, Inc. 2015 Employee Stock Purchase Plan.

Content

On December 15, 2023, Mr. Dolan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan.

Included in this number are 40,075 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 3,852 of which were granted on March 8, 2022 and shall vest through March 8, 2025 and 121 additional shares purchased pursuant to the DexCom, Inc. 2015 Employee Stock Purchase Plan.